Drug for treating hepatitis B

Abstract

A drug for treating hepatitis B is characterized by being made from the mixture of bupleurum, gardenia, radix scutellariae, isatis root, salvia miltiorrhiza, herba artemisiae capillaris, rhubarb, rhizoma coptidis, cyperus rotundus, desmodium, rhizoma sparganii, endothelium corneum gigeriae galli, Chinese angelica, dried rhizome of rehmannia, radix aucklandiae, dried tangerine peel, sealwort, malt,hawthorn, medicated leaven, semen plantaginis, poria, turtle shell, date and gentian. The drug has simple process, the effects of adjusting immunologic function, inducing the occurrence of interferon, inhibiting and eliminating hepatitis B virus, promoting hepatocyte repair, improving liver microcirculation and promoting the reliable treating effect of hepatitis B antigen negative conversion, short treating period, fast effect, no relapse after cure and low cost. The drug is handed down from the ancestor over 200 years before and cures tens of thousands of patients with the effective rate upto 100 percent.

Description

technical field [0001] The invention relates to a traditional Chinese medicine, in particular to a pure traditional Chinese medicinal composition for treating hepatitis B. Background technique [0002] HBV infection is the most common viral disease, affecting approximately 300 million people worldwide. So far, there is only one drug approved for the treatment of hepatitis B—interferon. In addition to causing influenza-like syndrome, the application of interferon can also cause leukopenia, thrombocytopenia, hair loss, depression, etc., sometimes because of toxic side effects. Frustrated, and its price is also relatively expensive. Lamivudine is the first nucleoside drug approved for the treatment of hepatitis B. However, the incidence of drug resistance during treatment is as high as 49%. Most patients rebound after drug withdrawal, and a few cases even lead to severe illness hepatitis. Another problem that anti-HBV drugs exist is that the patient's "response rate" is not ...

AI Technical Summary

Problems solved by technology

[0003] Chronic hepatitis B is a complex and changeable disease. Under the action of antiviral drugs and the immune pressure of the human body, the virus often mutates, which can lead to treatment failure

During the course of treatment, the patient's condition often fluctuates and occurs repeatedly. In addition, the immune function of chronic hepatitis B patients is dysfunctional, and "mixed infections" may occur during treatment, such as hepatitis B + hepatitis C, hepatitis B + hepatitis D, hepatitis B + hepatitis A, etc., or hepatitis B Combined with fatty liver, sometimes due to abuse of drugs, drinking, etc., making the condition complicated and more difficult to treat